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Abstract  
Objective. Fetal aortic stenosis may progress to hypoplastic left heart syndrome. Fetal 
valvuloplasty (FV) has been proposed to improve left heart hemodynamics and maintain a 
biventricular circulation (BV). We assessed FV efficacy by comparing survival and postnatal 
circulation between FV (performed between 2005 and 2012) and natural history (NH) cohorts 
in a retrospective, multicenter study. 
Methods. Main outcome measures were overall survival, BV survival, and survival after birth. 
Secondary outcomes were hemodynamic change, and left heart growth. We created a 
propensity score model including 54/67 FV and 60/147 NH fetuses. Analyses used logistic, 
Cox, or linear regression models with inverse probability of treatment weighting (IPTW), 
restricted to fetuses with propensity score 0.14-0.9 to create a final cohort for analysis of 42 
FV and 29 NH.  
Results. FV was technically successful in 59/67 at median age 26 weeks (21-34). There was 
a 7/72 (10%) procedure-related loss and 22/53 (42%) FV babies were delivered at <37 
weeks. IPTW demonstrated improved survival of liveborn infants following FV: HR 0.38 
(95%CI: 0.23-0.64), p=0.0001, after adjusting for circulation and postnatal surgical 
center. Similar proportions were BV: FV 36% and NH 38% and survival was similar 
between final circulations. Successful-FV showed improved hemodynamic response, 
and less deterioration of left heart growth, compared with NH (p=0.01 to 0.002). 
Conclusions. We report improvements in fetal hemodynamics and preservation of left heart 
growth following successful-FV compared to NH. While the proportion of those achieving a 
BV outcome was similar in both cohorts, FV survivors showed improved survival independent 
of final circulation out to 10 years. However, FV is associated with a 10% procedure-related 
loss and increased prematurity compared with NH and therefore the risk-benefit ratio 
remains uncertain. We recommend a carefully designed trial, incorporating appropriate and 
integrated fetal and postnatal management strategies to account for center-specific 
practices, so that the benefits achieved by fetal therapy versus surgical strategy can be 
clearly demonstrated. 
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INTRODUCTION 
A proportion of fetuses with aortic valve stenosis (AoS) will evolve into hypoplastic left heart 
syndrome before birth requiring postnatal univentricular (UV) palliation.[1-3] Fetal aortic 
valvuloplasty (FV) has been developed for the treatment of AoS during the past 15 years, 
with the intention of improving fetal left heart hemodynamics and promoting growth to 
achieve a biventricular circulation (BV).  
Single center studies have reported BV outcomes in one to two-thirds of fetuses with AoS 
undergoing FV[4-5] and an international, anonymized registry reported 43% BV compared 
with 20% untreated.[6] In our natural history (NH) AoS study, 33% of those fulfilling 
hypothetical FV selection criteria had BV.[2,5]  
The Fetal Working Group of the Association for European Paediatric and Congenital 
Cardiology established a retrospective, European study to assess the benefits of FV.  
We present survival and circulation following FV and, uniquely, compare these with 
contemporaneously enrolled NH cases, sharing similar characteristics at presentation but not 
undergoing FV. 
 
METHODS 
Six centers performing FV in Europe submitted their outcome data on fetal AoS and their NH 
cases collected contemporaneously from January 2005 to May 2012, with follow-up to April 
2017. A further 17 fetal centers in 13 countries submitted NH data over the same time period 
and the live-born children were treated in one of 16 postnatal centers. Inclusion criteria were 
usual atrial arrangement, concordant atrio-ventricular and ventriculo-arterial connections and 
stenosed, but still patent aortic valve. No fetuses with non-cardiac congenital malformations 
were enrolled. No maternal conditions or multiple pregnancies were excluded.  
NH data reported here were recently published [2] and pre-intervention echocardiograms 
from 109 neonates were reported in a blinded study of surgical decision-making.[7] 
The Ethics Committee at Imperial College London, considered the study audit of practice and 
no ethical approval was required.  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
Morphological and physiological data was entered into a standardised form by fetal 
cardiologists in participating centers as previously described.[2]  
AK added missing measurements from available clips. Data included right and left-sided 
valve and ventricular dimensions and cardiac Doppler, including the aortic and mitral valve 
pressure drop. Doppler waveforms of systemic and pulmonary veins, the ductus venosus, 
across the foramen ovale and the aortic and ductal arches were assessed and fetuses with 
bidirectional or retrograde flow along most of the transverse aortic arch were classified as 
retrograde flow. Demographic data, technical procedures and follow-up data were collated by 
AK and AO, who calculated gestational age Z-scores for cardiac dimensions.[8]  
All FV fetuses analysed had AoS as the major lesion, defined as stenotic, but patent, aortic 
valves with qualitatively depressed left ventricular (LV) function and all but one had 
retrograde arch flow. Primary outcome measures were survival and circulation. Secondary 
outcome measures were changes in fetal hemodynamics and left heart growth.  
All centers performed FV percutaneously under ultrasound guidance using needles between 
15-20 cm and 18-16 gauge and coronary artery balloon sizes 2.0-4.0 mm with balloon:aortic 
valve ratio of 0.7-1.3. Definition of technically successful FV (successful-FV) was placing a 
balloon across the aortic valve, with balloon inflation resulting in increased flow, with or 
without new regurgitation.[4,5] Procedure-related events were defined as demise, or delivery 
resulting in death, within 24 hours of FV. A Technical Supplementary File provides further 
procedural and technical details and Supplementary Table A includes outcomes for FV cases 
in chronological order, by FV center with outcomes to April 2017. 
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Propensity score 
Propensity score was used to assess the likelihood of a fetus with AoS receiving FV, 
enabling a retrospective pseudo-randomization of enrolled cases, in a two-stage process:  
1. Propensity score was derived from clinically important variables (Data Analysis). Eligible 
FV cases included successful-FV, unsuccessful-FV, and FV-related demises. All liveborn 
cases were required to have had postnatal intervention for AoS and known outcomes 
with adequate data. We excluded spontaneous intrauterine fetal demise (sIUFD) and 
termination of pregnancy. Propensity score selected 54/67 FV (43 successful-FV, five 
unsuccessful-FV and six FV-related demises) and 60/80 NH. 
2. Propensity score cases were weighted and restricted to within designated limits (0.14 to 
0.9) to provide comparative cohorts[9] using inverse probability of treatment weighting 
(IPTW) analyses. The final cohort for analysis was 42 FV and 29 NH.[9]  
 
We tracked physiological changes and growth from first or immediate pre-FV 
echocardiograms to delivery. Hemodynamic change of Doppler profiles through the foramen 
ovale, mitral valve and aortic arch were documented. Supplementary Table B describes the 
relative weighting assigned to each Doppler flow based on clinical consensus of the authors. 
This enabled a comparison of hemodynamic changes during pregnancy and these, and 
changes in left heart Z-scores were compared between three propensity score cohorts: 
successful-FV, unsuccessful-FV, and NH. 
 
The postnatal surgical pathway was considered UV if first surgery was Norwood or Hybrid 
and BV if it was aortic valvuloplasty (balloon or surgical) or Ross/Ross-Konno. BV-UV 
conversion was initial BV intent followed by subsequent UV surgery (Norwood or Hybrid), 
independent of its timing. There were no UV-BV conversions. Survival was compared for 
final BV and UV pathways.  
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Data analysis 
Frequencies and descriptive statistics summarized baseline characteristics by cohort. We 
developed propensity score for inverse probability of treatment weighting (IPTW) analyses to 
compute the average treatment effects of FV (whether successful-FV or not), accounting for 
potential confounding by observed baseline characteristics. Logistic model predictors to 
calculate propensity score included: gestational age at first scan; restrictive foramen ovale; 
aortic arch and foramen ovale flow directions, aortic and mitral valve diameter Z-scores, 
mitral valve inflow Doppler pattern, left ventricular inlet length Z-score, left-right ventricular 
inlet-length ratio, hydrops and large center effect for fetal and postnatal treatment. A large 
center was defined as one contributing 10 or more of both FV and postnatal procedures to 
the study. The aortic valve pressure gradient at presentation was left out of the propensity 
score model since it did not improve balance of baseline covariates.  
Weights were calculated as the inverse of propensity score. To obtain acceptable balance in 
baseline covariates, we restricted all IPTW analyses to observations with propensity score 
0.14-0.90.[9]  
Overall survival and BV survival (from fetal therapy to successful surgery) were compared 
between FV and NH, using an IPTW logistic regression model with cohort as a covariate. 
Estimated odds ratio (OR) and 95% confidence interval (CI) are reported. Secondary 
analyses were performed, adjusted for a subset of 6 covariates: gestational age at first scan; 
mitral valve inflow Doppler; Mitral and aortic valve Z-scores; left-right ventricular inlet-length 
ratio and hydrops.  
Liveborn survival was compared between FV and NH using Kaplan-Meier survival curves 
and Cox regression with IPTW adjusting for circulatory type and clustering of postnatal 
surgical center. Similarly, we compared survival in four groups for final circulation, including 
only successful-FV: FV-BV, FV-UV, NH-BV and NH-UV. 
Differences between the pre-FV and last fetal echo in left heart growth and hemodynamics 
were compared among successful-FV, unsuccessful-FV and NH cohorts using linear 
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regression with IPTW. Statistical significance was defined as p<0.05. All analyses were 
conducted in Stata 14.2 (Stata Corp, College Station, TX). 
 
RESULTS 
Entire FV cohort 
Sixty-seven fetuses undergoing FV were reported from six centers. Median age at referral for 
FV was 25 (range: 15-33) weeks, and the procedure performed at median 26 (21-34) weeks. 
There were 72 procedures: three had repeat FV, one was unsuccessful on both occasions 
and one repeat FV had been thought successful initially, one month previously. Interatrial-
septum ballooning/stenting was performed in two cases after FV (repeated in one). Figure 1 
shows outcomes for the entire FV cohort and Supplementary Table A shows outcome data to 
April in chronological order of procedure.  
FV-related death occurred in 7/72 (10%) procedures, including six considered successful-FV. 
Rare adverse events included left ventricular thrombus formation and balloon rupture. One 
serious maternal complication (placental abruption) resulted in a 25-weeks’ gestation 
delivery. Fifty-nine fetuses had successful-FV and 19/43 (44%) treated neonates were BV.  
Eight fetuses had unsuccessful-FV: 1/8 developed intact atrial septum resulting in fetal 
demise; 4/5 survivors were UV; 1/5 with retrograde arch flow and monophasic mitral valve 
inflow is BV alive at 5.7 years without pulmonary hypertension. 
Hydrops was present in 24/59 successful-FV and resolved in 9/24 affected fetuses. The 
course and outcomes are in Table 1. One additional case presented with hydrops that did not 
resolve, after unsuccessful-FV at 21 gestational weeks, and resulted in sIUFD. 
Sustained hemodynamic improvement was documented in 29/43 (67%) successful-FV 
undergoing postnatal procedures, with temporary improvement in another five (12%). One 
fetus with BV outcome improved initially, but subsequently developed intact atrial septum 
and hydrops. Four with UV outcome showed no hemodynamic improvement, or deteriorated 
following FV; one had inadequate follow-up data to evaluate change. Seven of eleven (64%) 
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fetuses with subsequent BV-UV conversions showed sustained hemodynamic improvement 
after FV and two showed temporary improvement. Following unsuccessful-FV, the five 
liveborn demonstrated no fetal hemodynamic improvement and only one achieved BV. 
Median gestational age at delivery was 38.0 weeks (range: 25.0-41.4), but 21/51 (41%) were 
delivered before 37+0 weeks, compared with 22/85 (26%) of our NH cohort.[2] Outcomes 
following premature delivery were similar in both cohorts; with 2/3rds surviving (70% of whom 
were BV). Birthweight was <10th centile in 11 in each cohort, but all but one of these 
delivered at term. The children underwent median three procedures (range 1-12). Six 
neonates had persistent pulmonary hypertension (one demised from multiorgan failure 
before procedure and five had BV procedures with one survivor to three years). Three 
children had late-onset pulmonary hypertension: one after Norwood, delaying the Glenn, but 
Fontan was completed and now alive on Sildenafil, aged five. Two others were BV-UV 
conversions (one early and one aged 18 months), both demised. Seven of these nine were 
included in the weighted analysis. 
 
Propensity Score Modelling and IPTW Analysis 
Table 2 compares the baseline characteristics of the first scan used to derive the propensity 
score model and IPTW cohort used in the weighted analyses, resulting in between-group 
balance on baseline characteristics with standardized differences of 0.14 or less. The 
postnatal circulatory outcomes for the liveborn weighted cohorts were similar at 36-38% 
(Table 3). 
Survival and circulatory outcomes 
Overall survival was similar in both cohorts: OR 1.57, (95%CI: 0.72-3.41), p=0.25, and 
for BV survival: OR 1.31, (95%CI: 0.23-7.48), p=0.76. Secondary analyses adjusting for 
additional covariates gave similar results (not shown).  
The six procedure-related fetal deaths were removed to create survival analyses of 
livebirths. The age of first postnatal procedure was similar in both cohorts: median (range) 
was six (1-56) days for FV and four (1-74) for NH. IPTW Cox-regression analysis, 
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adjusting for clustering due to surgical center, showed FV conferred postnatal survival 
advantage after adjusting for circulation (HR 0.38, (95%CI: 0.22-0.64), p=0.0001) 
(Figure 2). The final circulations were compared for each cohort (after removing 
unsuccessful-FV) and survival out to 10 years was similar: HR 0.54, (95%CI: 0.14-
2.08), p=0.37 (Figure 3). Pairwise comparisons of the marginal linear predictions is 
included as Supplementary Table C. 
Fetal hemodynamics and left heart growth  
The IPTW analysis shows hemodynamic improvement was significantly better following 
successful-FV than in those with a failed attempt, but did not differ significantly from NH. 
However left heart growth was significantly worse in NH than successful-FV (Table 4). The 
small number of technically unsuccessful cases appeared to show similar left ventricular and 
aortic valve growth to the successful-FV cohort, but had a significantly reduced mitral valve 
size by delivery. The hemodynamic and left heart growth data used to create the propensity 
score is included in Supplementary Table D. 
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DISCUSSION 
During the study period the selection of cases for FV was evolving worldwide. Initially, fetal 
cardiologists hoped that FV could achieve a biventricular circulation in fetuses with short left 
ventricles and endocardial fibroelastosis, compared to natural history. Subsequent 
experience has shown that only selected fetuses appear to benefit, however selection criteria 
remain elusive. 
As a prospective randomised controlled trial was not feasible, we used a propensity score to 
provide pseudo-randomisation of our retrospective data. We observed similar proportions 
with BV outcomes in our IPTW, intention-to-treat cohorts: 36% (FV) and 38% (NH). 
IPTW logistic analysis showed FV did not confer survival or circulatory benefits but, when 
procedure-related deaths were removed and Cox-regression adjusted for circulation and 
surgical center, FV reduced the risk of early postnatal death by two-thirds. Survival out to 10 
years in this cohort was similar for final BV and UV circulations, with no deaths after 2.3 
years. 
FV was introduced into clinical practice without a trial and many centers performed 
procedures without reporting outcomes. An international, anonymized registry was recently 
established to collect multicenter data, but currently lacks independent audit, making data 
validation difficult.[6] Contemporaneously matched controls (rather than choosing those with 
unsuccessful-FV) and treatment randomization are missing from FV publications,[1,4-
6,10,11] providing only level three evidence of treatment efficacy.[7]  
Our study contributes to the global experience of FV and is strengthened by 
contemporaneously collected NH controls. Several important observations can be drawn. 
Firstly, our 10% procedure-related loss was similar to single-center studies [4,5,9] and less 
than the 17% from the anonymized registry,[6] highlighting the importance of experienced 
teams mentoring new FV centers. Secondly, fetal Z-scores demonstrated favourable 
anatomy for FV, indicating good case selection. Thirdly, the operators’ evaluation of FV-
success was accompanied by objective changes in fetal hemodynamics: hydrops resolved in 
over one-third of affected fetuses and two-thirds of all successful-FV showed sustained 
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hemodynamic improvement, including reversal of previously retrograde arch and foramen 
flow and new biphasic ventricular filling. These individuals had BV outcomes more 
commonly.  
The prevalence of premature delivery (<37+0 weeks) has not been reported following FV. 
Premature delivery occurred in 42% FV compared to 26% (22/85) NH. From the limited 
maternity data we collected, growth restriction (<10th centile) was not responsible for early 
delivery as it occurred almost exclusively in those delivering >37 weeks. Early delivery may 
represent institutional practice (unsubstantiated by evidence) to avoid worsening left heart 
function and aortic valve closure and in this study was more frequent following a fetal 
intervention. Delivery was not centralised to the site performing the FV and lack of familiarity 
in disease assessment may be a contributing factor. 
Recognition that left heart growth remains suboptimal following successful-FV has resulted in 
modifications to selection criteria. Although important in long-term ventricular function, the 
diagnosis and grading of endocardial fibroelastosis by ultrasound remains elusive due to 
poor accuracy in comparison with histology.[12] Although it was originally included as a 
prediction variable[13], it has recently been removed due to the qualitative nature of grading 
and only modest interobserver reliability.[12,14] Newer selection criteria include left 
ventricular inlet length Z-score>0 at presentation and pressure generation>=20 mmHg.[4-5] 
While one group applied the 2010 criteria hypothetically to a small series and described it as 
predictive of outcome,[3] our larger dataset suggests otherwise. Of 40 NH fetuses satisfying 
criteria for emerging hypoplastic left heart syndrome, 13 (33%) had BV despite eight falling 
below the threshold score to be theoretically offered FV.[2] Importantly, our hemodynamic 
and left heart growth data suggest that outcomes following unsuccessful-FV are not similar to 
NH, making unsuccessful-FV unsuitable as controls.  
Prospective fetal therapy trials for open meningomyelocele surgery and laser therapy for 
twin-to-twin transfusion syndrome[15,16] demonstrate that successful fetal procedures rely 
on: case selection, technical prowess and integrated postnatal management. Therefore, 
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refinement of FV selection criteria, unsupported by a trial, may increase the chance that FV 
is offered to those who would achieve BV without fetal therapy, with the associated risks of 
procedure-related mortality and fetal and/or maternal morbidity.  
We have previously discussed postnatal selection bias and its effects which touches upon 
the ethos and ability of the entire pre- and postnatal team in decision making.[7] We note BV 
survival is relatively low in our study, similar to survival to hospital discharge of 58%, 
(irrespective of FV) in a recent multicentre registry report, and less than that of a single 
center report.[6,11] Poor outcome may be associated with the complexity of congenital AoS 
resulting in multiple procedures in addition to premature delivery.  
Unrecognized center-specific differences in delivering affected babies preterm to initiate 
earlier treatment, decision-making regarding postnatal management, skill and practice may 
potentially confound our results, even though we accounted for surgical center variability in 
our analyses. The postnatal treatment centers had different postnatal strategies, in part 
because the range of surgical options were not available in all cardiac surgical centers in this 
study.[17-21] An aggressive approach may preclude later conversion to UV and result in 
early mortality and the risk of later pulmonary hypertension.[11,17-22] 
 
STUDY LIMITATIONS 
Limitations of our study include its retrospective, multicenter design with a limited cohort size. 
Low rates of prenatal diagnosis[23] make a prospective, randomized FV trial challenging, 
therefore, we used IPTW in our study to minimize the deficiencies in our dataset.  
Although the number of postnatal cardiac centers may have introduced unrecognised 
confounding and bias into the assessment of the efficacy of FV in this study, the statistical 
model we used adjusted for clustering due to center influence. 
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CONCLUSIONS 
We report improvements in fetal hemodynamics and preservation of left heart growth 
following successful-FV compared to NH. While the proportion of those achieving a BV 
outcome was similar in both cohorts, FV survivors showed improved survival independent of 
final circulation out to ten years. However, FV is associated with a 10% procedure-related 
loss and increased prematurity compared with NH and therefore the risk-benefit ratio 
remains uncertain.  
We recommend a carefully designed trial, incorporating appropriate and integrated fetal and 
postnatal management strategies to account for center-specific practices, so that the benefits 
achieved by fetal therapy versus surgical strategy can be clearly demonstrated. 
 
Data presented previously: in addition to the publications declared in the text, the initial 
analysis of the entire cohort out to 2014 was awarded the prize for top scoring abstract in the 
Cardiovascular Disease in the Young category, American Heart Association 2014, Chicago, 
USA and the presentation “Does fetal aortic valvuloplasty alter the natural history of aortic 
stenosis?” was presented orally. 
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Figure Legends 
Figure 1. Outcomes for fetal aortic stenosis cohort undergoing fetal valvuloplasty. Fetuses 
used in propensity score shown in bold. 
 
AoS, Aortic Stenosis; AoV, postnatal balloon aortic valvuloplasty or surgical valvotomy as the 
first and only procedure, but may have been repeated; AoV+arch+MV, postnatal balloon 
aortic valvuloplasty or surgical valvotomy followed by arch and mitral valve surgery; 
AoV+Ross or RK, postnatal balloon aortic valvuloplasty or surgical valvotomy followed by 
Ross or Ross-Konno surgery; ASD, atrial septal defect closure; BV, biventricular circulation; 
CoA, coarctation of the aorta; FV, fetal valvuloplasty; Hybrid, Hybrid procedure; sIUFD, 
spontaneous intra-uterine fetal demise; NH, natural history; NW, Norwood procedure as 
primary surgery with the intention to follow a univentricular circulation; PHT, pulmonary 
hypertension; TOP, termination of pregnancy; UV, univentricular circulation. 
Figure 2. Kaplan-Meier curves comparing survival between the Inverse Probability of 
Treatment Weighting (IPTW) cohorts.  
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The fetal valvuloplasty (FV) cohort includes both technically successful-FV and unsuccessful-
FV cases on an intention to treat basis. The six procedure-related fetal deaths were 
removed to create the survival analyses of live births. The actual number of individuals 
included at each time period is documented below the curves (although weighted values 
were used in the analysis and curves). IPTW Cox-regression analysis, adjusting for 
clustering due to surgical center, showed FV conferred a survival advantage after birth 
(HR 0.38 (95% CI: 0.22-0.64), p=0.0001), even after adjusting for circulation and 
postnatal treatment center. Time zero represents birth.  
 
FV, fetal valvuloplasty; NH, natural history. 
 
Figure 3. Kaplan-Meier curves comparing survival for the final circulation between the 
Inverse Probability of Treatment Weighting (IPTW) cohorts.  
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The fetal valvuloplasty (FV) cohort in this graph comprises only technically successful FV 
cases. The actual number of individuals included at each time period is documented below 
the curves. IPTW Cox-regression analysis, adjusting for clustering due to surgical 
center, showed no difference in survival between the postnatal circulations in the FV 
cohort (HR 0.54 (95% CI: 0.14-2.08), p=0.37), after adjusting for postnatal treatment 
center. Time zero represents birth.  
FV, technically successful fetal valvuloplasty; NH, natural history. 
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Tables 
Table 1. Details and outcomes of fetuses with hydrops undergoing technically successful 
fetal valvuloplasty 
 
Hydrops  
group 
GA at FV  
(weeks) 
GA at birth  
(weeks) 
Circulatory 
Outcome 
Follow-up age  
(years) 
 
1. resolved 23 41.4 CC  
 21 36.4 UV dead 0.003 
 22 39.0 UV alive 3.7 
 26 40.0 UV alive 6.5 
 25 34.7 BV alive 10.1 
 26 39.1 BV alive 5.7 
 27 32.9 BV alive 6.7 
 28 34.4 BV alive 11.5
 33 36.9 BV alive 11.4 
2. developed / not 
resolved 
21 - sIUFD  
 23 - sIUFD  
 25 - TOP  
 26,30 - CC  
 30 40.0 UV alive 6.7 
 24 40.0 BV alive 4.9 
 30 33.6 BV alive 7.5 
3. presented / not 
resolved 
28 - sIUFD  
 29 - sIUFD  
 25 25.0 FV-NND 0.003 
 27 39.0 NND (pre 
surgery) 
0.027 
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 26,27 36.6 BV-UV dead 0.014 
 24 37.1 BV dead 0.125 
 31 39.0 BV dead 0.25 
 30 36.0 BV-UV alive 5.5 
 
Hydrops groups: Group 1. Nine presented with hydrops at first fetal echo and resolved after 
FV; Group 2. Seven developed hydrops after the first fetal echo and it did not resolve after 
FV; Group 3. Eight presented with hydrops at first fetal echo that did not resolve after FV 
Bold indicates case included in inverse probability of treatment weighting (IPTW) cohort.  
BV, Biventricular circulation;  BV-UV, biventricular to univentricular conversion; CC, Comfort 
care;  FV, fetal aortic valvuloplasty;  FV-NND, neonatal death related to FV;  GA, gestational 
age;  NND, neonatal death;  sIUFD, spontaneous intrauterine death;  TOP, termination of 
pregnancy;  UV, Univentricular circulation.   
 
Table 2. Baseline characteristics at first scan used to derive the propensity score model and 
the inverse probability of treatment weighting cohorts 
 Whole Cohort (with sufficient data) Inverse Probability of Treatment 
Weighting Cohort 
 FV 
(n=55) 
NH 
(n=80) 
Standardized 
Difference 
FV* 
(n=42) 
NH* 
(n=29) 
Standardized 
Difference 
Gestational Age 25.7 ± 
3.7 
25.4 ± 
4.7 
0.08 25.7 ± 3.7 25.5 ± 
4.8 
0.06 
Aortic valve Z-
score 
-1.3 ± 
1.34 
-1.62 ± 
2.15 
0.17 -1.64 ± 
1.32 
-1.51 ± 
2.07 
-0.08 
Mitral valve Z-
score 
-0.97 ± 
1.96 
-2.21± 
2.43 
0.54 -1.85 ± 
1.99 
-2.00 ± 
1.93 
0.08 
LV:RV length ratio 1.03 ± 
0.23 
0.97 ± 
0.22 
0.26 0.99 ± 0.23 0.99 ± 
0.20 
0.01 
FO right-to-left 
flow 
1/54 (2) 26/72 
(36) 
-0.97 1 (4) 1 (4) -0.01 
AoA retrograde 
flow 
54/55 
(98) 
42/80 
(53) 
1.25 34 (97) 35 (98) -0.08 
Mitral valve 
biphasic flow 
17/55 
(31) 
39/68 
(57) 
-0.55 7 (20) 7 (19) 0.02 
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Hydrops 12/55 
(22) 
3/80 (4) 0.56 2 (7) 1 (4) 0.14 
LV inlet length Z-
score 
-0.47 ± 
1.55 
-1.04 ± 
2.03 
0.30 -0.80 ± 
1.74 
-0.69 ± 
1.88 
-0.06 
Large Center    15 (44) 14 (38) 0.11 
AoVPG**    16.2 ± 14.3 15.0 ± 
11.8 
0.09 
 
Numbers are presented as mean ± SD or N (%), *Numbers are inverse probability-weighted, 
**Not included in propensity score model.  
AoA, aortic arch; AoVPG, aortic valve pressure gradient; FO, foramen ovale; FV, fetal 
valvuloplasty; NH, natural history; LV / RV, left / right ventricle; Large Center, number of 
cases presenting for FV and/or postnatal surgery at one or more of the larger centers 
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Table 3.  Final postnatal circulation for the liveborn inverse probability of treatment 
weighted cohort. 
 
Final Circulation FV NH Total 
BV 
 
13 (36.1) 11 (37.9) 24 
BV-UV 
 
10 (27.8) 4 (13.8) 14 
UV 
 
13 (36.1) 14 (48.3) 27 
Total 
 
36 29 65 
 
Numbers are presented as N (%), FV, fetal valvuloplasty; NH, natural history; BV, 
biventricular; UV, univentricular 
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Table 4. Change in fetal hemodynamics and left heart growth during pregnancy, for inverse 
probability of treatment weighting (IPTW) cohorts 
 
 FV Technical Success FV No Technical Success Natural History 
n First Last Δ n First Last Δ p* n First Last Δ p* 
Aortic valve  
Z-score 
 
3
2 
-
1.29 
(1.1
7) 
-1.5 
(1.5
5) 
- 
0.21 
(1.5
3) 
6 -
1.78 
(1.7
5) 
-
3.04 
(1.0
2) 
- 
1.26 
(1.6
8) 
0.0
9 
1
9 
-
2.38 
(2.2
2) 
-
3.12 
(2.4
0) 
- 
0.74 
(3.0
6) 
0.0
1 
Mitral valve  
Z-score 
 
3
2 
-
1.25 
(1.9
1) 
-
1.24 
(1.5
5) 
0.01 
(1.9
8) 
5 -
2.07 
(1.1
6) 
-
3.42 
(1.4
6) 
- 
1.35 
(1.1
8) 
0.0
4 
1
7 
-
2.48 
(1.6
0) 
-
3.41 
(2.3
7) 
- 
0.93 
(2.7
8) 
0.0
2 
LV-inlet 
length  
Z-score  
 
3
1 
-
0.46 
(1.6
7) 
-
1.14 
(1.9
7) 
- 
0.69 
(1.3
3) 
6 -
1.63 
(1.3
5) 
-2.3 
(2.0
1) 
- 
0.67 
(1.0
5) 
0.8
3 
2
0 
-
1.21 
(1.7
3) 
-
3.21 
(2.6
3) 
- 
2.01 
(2.5
8) 
0.0
02 
LV-EDD  
Z-score 
 
3
1 
0.96 
(1.9
2) 
0.36 
(2.2
3) 
- 
0.61 
(2.0
1) 
5 -
0.86 
(1.2
3) 
-
0.34 
(1.3
4) 
0.52 
(1.2
2) 
0.1
1 
1
9 
0.34 
(1.7
0) 
-
1.64 
(2.7
4) 
- 
1.99 
(2.6
4) 
0.0
06 
Hemodyna
mics 
weighted 
score 
2
6 
14.1
5 
(2.9
2) 
 
11.1
5 
(4.8
8) 
 
3.00 
(4.7
2) 
 
6 16.6
7 
(2.0
4) 
 
16.2
5 
(1.3
7) 
 
0.42 
(1.0
2) 
 
0.0
4 
1
6 
14.0
3 
(3.4
4) 
 
12.7
2 
(4.3
2) 
 
1.31 
(2.7
3) 
 
0.0
9 
Median 
(IQR) 
 15  
(12.
5-
15) 
10.2
5  
(9.5
-15) 
2.75 
(0-
5) 
 16.2
5  
(15-
17.5
) 
16.2
5  
(15-
17.5
) 
0  
(0-
0) 
  15 
(14.
5-
15) 
14.5  
(10-
15) 
0  
(0-
3.5) 
 
 
Values are expressed as mean (sd) except where stated as median (IQR) 
* p: comparison of difference (Δ) between FV technical success group and the other two 
cohorts, from inverse probability of treatment weighting (IPTW) regression 
FV, fetal valvuloplasty; LV, left ventricle; EDD, end diastolic diameter 
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